BR0008468A - Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos - Google Patents

Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos

Info

Publication number
BR0008468A
BR0008468A BR0008468-9A BR0008468A BR0008468A BR 0008468 A BR0008468 A BR 0008468A BR 0008468 A BR0008468 A BR 0008468A BR 0008468 A BR0008468 A BR 0008468A
Authority
BR
Brazil
Prior art keywords
hormone
same
agonist
antagonist
aspects
Prior art date
Application number
BR0008468-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Christian Grondahl
Thomas Host Hansen
Alexander Ruebig
Christa Hegele-Hartung
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BR0008468A publication Critical patent/BR0008468A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C12N2501/392—Sexual steroids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR0008468-9A 1999-02-24 2000-02-23 Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos BR0008468A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199900255 1999-02-24
US13081699P 1999-04-23 1999-04-23
DKPA199901310 1999-09-16
PCT/DK2000/000074 WO2000050066A1 (en) 1999-02-24 2000-02-23 Treatment of infertility

Publications (1)

Publication Number Publication Date
BR0008468A true BR0008468A (pt) 2002-02-05

Family

ID=27220546

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0008468-9A BR0008468A (pt) 1999-02-24 2000-02-23 Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos

Country Status (13)

Country Link
US (1) US6585982B1 (zh)
EP (1) EP1156822B1 (zh)
JP (1) JP2002537349A (zh)
KR (1) KR20010093280A (zh)
CN (1) CN1353617A (zh)
AT (1) ATE317266T1 (zh)
AU (1) AU2794100A (zh)
BR (1) BR0008468A (zh)
CZ (1) CZ20012967A3 (zh)
DE (1) DE60025905T2 (zh)
ES (1) ES2258445T3 (zh)
HU (1) HUP0200157A3 (zh)
WO (1) WO2000050066A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
IL144529A0 (en) * 1999-02-26 2002-05-23 Novo Nordisk As Meiosis activating sterol augments implantation rate
MXPA02007818A (es) * 2000-02-25 2002-10-23 Schering Ag Tasa de implantacion mejorada utilizando ff-mas.
WO2001062260A2 (en) * 2000-02-25 2001-08-30 Schering Aktiengesellschaft Improvement of implantation rate
WO2001088098A2 (en) * 2000-05-18 2001-11-22 Schering Aktiengesellschaft Fertilization of aged oocytes
EP1287033A2 (en) * 2000-05-25 2003-03-05 Queen's University At Kingston Pt32 sperm protein, sperm c-yes, oocyte cytoplasmic c-yes, and uses thereof
EP1216701A1 (en) * 2000-12-22 2002-06-26 Schering Aktiengesellschaft Process to increase the concentration of meiosis-activating sterols (MAS) in the cholesterol synthesis and the use of potent inhibitors in the process
EP1245572A1 (en) 2001-03-26 2002-10-02 Schering Aktiengesellschaft Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation
ES2356895T3 (es) 2001-09-12 2011-04-14 Merck Serono Sa USO DE LA hCG Y LH EN LA HIPERESTIMULACIÓN OVÁRICA CONTROLADA.
AU2002324183B2 (en) * 2001-09-12 2007-10-25 Merck Serono Sa Use of hCG and LH in controlled ovarian hyperstimulation
MXPA04002256A (es) * 2001-09-12 2004-07-23 Applied Research Systems Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
WO2003070766A2 (en) * 2002-02-22 2003-08-28 Novo Nordisk A/S A transducer of mas signalling
JP2005518823A (ja) 2002-03-08 2005-06-30 マクギル・ユニバーシテイ 未成熟ヒト卵母細胞の体外成熟
UA81251C2 (en) * 2002-06-07 2007-12-25 Ares Trading Sa Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
WO2006001938A2 (en) 2004-05-17 2006-01-05 The General Hospital Corporation Methods and compositions for producing germ cells from bone marrow derived germline stem cells
KR101505202B1 (ko) 2006-03-07 2015-03-27 지타 쉬로프 인간 배아 줄기 세포 및 그의 유도체를 포함하는 조성물, 그의 사용 방법 및 제조 방법
CA2868239C (en) 2011-04-14 2018-07-31 The General Hospital Corporation Compositions and methods for autologous germline mitochondrial energy transfer
US9845482B2 (en) 2011-06-29 2017-12-19 The General Hospital Corporation Compositions and methods for enhancing bioenergetic status in female germ cells
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5563059A (en) * 1993-02-23 1996-10-08 Genentech, Inc. Use of human inhibin and human activin to increase the number of mature primate oocytes
US5716777A (en) * 1994-06-23 1998-02-10 Novo Nordisk A/S Regulation of meiosis using sterols
CZ279797A3 (cs) * 1995-03-06 1998-01-14 Novo Nordisk A/S Způsob stimulace miózy zárodečné buňky a použití sloučeniny, která způsobuje akumulaci látky aktivující endogenní miózu
CN1191543A (zh) * 1995-06-23 1998-08-26 诺沃挪第克公司 减数分裂调控化合物
WO1997000883A1 (en) * 1995-06-23 1997-01-09 Novo Nordisk A/S Meiosis regulating compounds
EP0946584B1 (en) * 1996-12-20 2003-04-23 Novo Nordisk A/S Meiosis regulating compounds
EP0988312B1 (en) * 1997-06-04 2002-04-03 Akzo Nobel N.V. 17beta-allyloxy(thio)alkyl-androstane derivatives for the modulation of meiosis
US5866599A (en) * 1997-06-06 1999-02-02 Basf Aktiengesellschaft Fungicidal mixtures
ATE361091T1 (de) * 1999-02-24 2007-05-15 Novo Nordisk As Behandlung von unfruchtbarkeit

Also Published As

Publication number Publication date
EP1156822B1 (en) 2006-02-08
ES2258445T3 (es) 2006-09-01
US6585982B1 (en) 2003-07-01
HUP0200157A2 (hu) 2002-05-29
AU2794100A (en) 2000-09-14
HUP0200157A3 (en) 2002-06-28
DE60025905T2 (de) 2006-09-14
EP1156822A1 (en) 2001-11-28
CZ20012967A3 (cs) 2001-12-12
DE60025905D1 (de) 2006-04-20
ATE317266T1 (de) 2006-02-15
WO2000050066A1 (en) 2000-08-31
CN1353617A (zh) 2002-06-12
KR20010093280A (ko) 2001-10-27
JP2002537349A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
BR0008468A (pt) Método para fertilização humana in vitro, uso de um hormÈnio hipotalânico e/ou hormÈnio pituitário ou de um agonista ou antagonista do mesmo ou de um derivado ativo do mesmo, kit farmacêutico em forma de dosagem única, e, qualquer novo aspecto ou combinação de aspectos
PL357944A1 (en) Intradermal-penetration agents for topical local anesthetic administration
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
BR9510168A (pt) Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição
ES2155124T3 (es) Composiciones farmaceuticas liquidas a base de hormonas tiroideas.
PL347671A1 (en) Compounds and compositions for delivering active agents
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
EP1762236A3 (en) Formulations of alpha adrenergic receptor antagonists and their uses
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DE60021059D1 (de) Hydrogelpartikel formulierungen
NO980700D0 (no) Perifert aktive anti-hyperalgesi opiater
BRPI0413028A (pt) composto, uso de um composto, composição farmacêutica, e, kit farmacêutico
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
BR0110079A (pt) Combinação de compostos orgânicos
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
BR9709062A (pt) Composto, composição farmacêutica, e, uso de um composto.
BR0313388A (pt) Método para tratar, remediar ou evitar a psorìase em um paciente, uso de um composto de antagonista de cgrp, composição farmacêutica para tratamento da psorìase, e, método para identificar um composto candidato para o uso em um medicamento para tratar a psorìase
BR9912827A (pt) Composições tópicas compreendendo um analgésico opióide e um antagonista de nmda
DE60019334D1 (de) Antivirale arznei
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
BR0015225A (pt) Tratamento de enfisema utilizando antagonistas retinóides seletivos para rar

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1925 DE 27/11/2007.